Rgenta Therapeutics, a Cambridge, MA-based biotechnology company, raised $52M in Series A funding.
The round was led by AZ-CICC Healthcare Investment Fund with participation from Korean Investment Partners, Delos Capital.
The company plans to use the funding to speed up the development of the lead programs, enhance target discovery, extend platform capabilities, and advance a pipeline of RNA-targeting programs against a range of disease indications.
Led by CEO Simon Xi, Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs.